CAS Number: 132-17-2
Therapeutic Category
Anti-Parkinson’s
Central Nervous System (CNS)
API Technology
Synthetic
Dose Form
Oral Solids
Injectable
Available Regulatory Filing
USA
Canada
Australia
New Zealand
Singapore
Innovator Brand (USA)
Cogentin
Mechanism of Action
COGENTIN possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism.
In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine.
In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.
Indication
For use as an adjunct in the therapy of all forms of parkinsonism.
Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines).